ArticleNorthern clinics of Istanbul2022
Evaluation of immunomodulatory nutrients in critically ill patients in the intensive care unit.
Article in Northern clinics of Istanbul, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Nutritional Challenges and Strategies in Obese Critically Ill Patients with Gynecological Cancer: A Narrative Review.Nutrients · 2026Review
- Immunonutrition in ERAS Protocol for Patients with Gynecologic Cancer: A Narrative Review of the Literature.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveGlutamine and omega-3 fatty acids have been shown to decrease infection rates, antibiotic use, and hospital length of stay. However, whether giving immunonutrients to critically ill patients is beneficial remains controversial. In our study, we aimed to look at the effectiveness of parenteral unsaturated (omega-3) fatty acids and amino acid glutamine in patients with serious conditions in the intensive care unit (ICU).
methodsThe data of patients, who received parenteral amino acid glutamine and unsaturated fatty acids (omega-3) in the ICU, were retrospectively analyzed. Eighty-four patients were classified with regard to the length of the immune modulatory nutrient treatment. Groups were constructed according to the length of the treatment in days: 9 days or more (Group I), 3-9 days (Group II), and <3 days (Group III). Demographic data, Acute Physiologic Assessment and Chronic Health Evaluation II Scores (APACHE-II), ICU and hospitalization periods, inotropic medication, 60
resultsDemographic data of the patients and APACHE-II scores among the groups were not significantly different from each other. ICU stay length, hospitalization length, positivity in bacterial cultures, and use of inotropic agents were significantly higher in Group I compare with other groups.
conclusionIn the ICU, it was observed that patients with multiorgan failure using parenteral unsaturated fatty acids and amino acid glutamine had longer hospital and intensive care stay. It can be said that long-term use of antioxidants and immunonutrition does not have a beneficial effect in patients with multiple organ failure with high APACHE-II scores.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.